As a chronic disease, spondyloarthritis presents a diverse spectrum of challenges for both patients and their treating physicians. While there have been many innovations to reduce delays to diagnosis and improve treatment options, there are still gaps within knowledge and understanding. Join us in September to learn insights and discuss the future direction of research to address these challenges.
| Time | ||||
| 5:30PM – 7:00PM | Welcome Reception at Bethesda Marriott Hotel | Bethesda, Maryland USA |
| 7:00 AM & 7:20 AM | Buses depart Bethesda Marriott Hotel | |||
| 8:00 AM | Registration and Breakfast | |||
| 8:30 AM | Welcome Remarks | Cassie Shafer, CEO | Spondylitis Association of America | Encino, CA USA |
| Introductions | Robert A. Colbert, MD, PhD | NIH/NIAMS | Bethesda, Maryland USA | |
| Kristi Kuhn, MD, PhD | University of Colorado | Denver, Colorado USA | ||
| 8:35 AM | SESSION I: ENDOTYPES | |||
| Are there disease endotypes in SpA and how would we define them? | Kristi Kuhn, MD, PhD | University of Colorado | Denver, Colorado USA | |
| How are endotypes currently defined in RA and how helpful are those definitions? | Kevin Deane, MD, PhD | University of Colorado | Denver, Colorado USA | |
| Are molecular endotypes based on RA synovial characteristics informative? | Laura Donlin, PhD | Weill Cornell Graduate School of Medical Sciences | New York City, New York USA | |
| How do we apply precision medicine in psoriatic arthritis? | Chris Ritchlin, MD, MPH | University of Rochester | Rochester, New York USA | |
| Panel Discussion | ||||
| 10:30 AM | Break | |||
| 10:45 AM | SESSION II: PAIN | |||
| How do we better address pain in our patients with axSpA? | Alexis Ogdie, MD, MSCE | University of Pennsylvania | Philadelphia, Pennsylvania USA | |
| How should we treat non-inflammatory pain? | Yvonne Lee, MD, MSSc | Northwestern University | Chicago, Illinois USA | |
| Novel insights into pain and how do we leverage them? | Anne-Marie Malfait, MD, PhD | Rush University | Chicago, Illinois USA | |
| Panel Discussion | ||||
| 12:15 PM | LUNCH | |||
| 1:15 PM | SESSION III: IMAGING | |||
| How can we do this better? Where are we going next? | Lianne Gensler, MD | University of California, San Francisco | San Francisco, California USA | |
| What is tomorrow’s path for advancing structural progression research in axSpA? | Denis Poddubnyy, MD, PhD | Charité University | Berlin, Germany | |
| Are there innovative imaging technologies that should be applied to SpA for diagnosis? How to get radiologists trained? | Lennart Jans, MD, PhD | Ghent University | Ghent, Belgium | |
| What role will AI play in the future of SpA imaging? | Sharmila Majumdar, PhD | University of California, San Francisco | San Francisco, California USA | |
| Panel Discussion | ||||
| 3:15 PM | Day 1 Concluding Remarks | Nigil Haroon, MD, PhD, MBA | University of Toronto | Toronto, Ontario Canada |
| 3:30 PM | Depart NIH to hotel | |||
| 6:00 PM – 7:00 PM | Abstract Poster Session Reception at hotel | Download Abstract Poster Session | ||
| 6:30 PM | DINNER at hotel |
| 7:00 AM & 7:20 AM | Buses depart Bethesda Marriott hotel | |||
| 8:00 AM | Breakfast | |||
| 8:30 AM | Welcome | |||
| 8:35 AM | SESSION IV: BIOLOGIC VARIABLES, SOCIAL CONSTRUCTS, AND HEALTH DISPARITIES | |||
| How do we address a range of disparities in SpA diagnosis, treatment, and research? | Maureen Dubreuil, MD, MSc | Boston University | Boston, Massachusetts USA | |
| What are the racial disparities in care? | Elizabeth Ferucci, MD, MPH | Alaska Native Tribal Health Consortium | Anchorage, Alaska USA | |
| How can we engage community in clinical research? | Hani El-Gabalawy, MD, FRCPC, FCAHS | University of Manitoba | Winnipeg, Manitoba Canada | |
| What are mitigating disparities in research participation?: lessons from lupus | Sarfaraz Hasni, MD | NIH/NIAMS | Bethesda, Maryland USA | |
| How can institutional approaches support equity in research? | Edith M. Williams, PhD, MS | University of Rochester Medical Center | Rochester, NY USA | |
| Panel Discussion | ||||
| 10:30 AM | BREAK | |||
| 10:45 AM | SESSION V: THERAPEUTICS | |||
| For what aspects of disease are therapeutic advancements most needed and how can we enhance evaluation of both emerging and existing therapies? | Pamela Weiss, MD, MSCE | Perelman School of Medicine at the University of Pennsylvania. | Philadelphia, Pennsylvania USA | |
| What are emerging therapies and targets & strategies? | Georg Schett, MD | Friedrich-Alexander-Universität | Erlangen, Germany | |
| Should we reconsider trial design? Do we have the right outcomes? | Laura Coates, MBChB, MRCP, PhD | University of Oxford | Oxford, England | |
| What is the role of complementary medicine and how do we study it? | Chenchen Wang, MD, MSc | Tufts University | Boston, Massachusetts USA | |
| Concluding Remarks | Robert A. Colbert, MD, PhD | NIH/NIAMS | Bethesda, Maryland, USA | |
| Kristi Kuhn, MD, PhD | University of Colorado | Denver, Colorado, USA | ||
| 12:40 PM | LUNCH | |||
| 1:00 PM | Depart NIH to hotel or airport |
Input your search keywords and press Enter.
